Stock Financial Ratios, Dividends, Split History

EYEG / Eyegate Pharmaceuticals Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price0.57
Volume2,231,500.00
Market Cap ($M)9.84
Enterprise Value ($M)2.22
Book Value ($M)-1.93
Book Value / Share-0.11
Price / Book-5.20
NCAV ($M)-7.77
NCAV / Share-0.45
Price / NCAV-1.27
Income Statement (mra) ($M)
Revenue0.41
EBITDA0.00
Net Income-13.22
Balance Sheet (mrq) ($M)
Cash & Equivalents7.81
Cash / Share0.45
Assets14.31
Liabilities16.23
Quick Ratio0.57
Current Ratio0.57
Share Statistics
Common Shares Outstanding17,257,255
Common Stock Shares Outstanding17,257,255
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)6.86
Return on Assets (ROA)-1.36
Return on Equity (ROE)40.12
Identifiers and Descriptors
CUSIP30233M107
Central Index Key (CIK)1372514
Industry Groups
SIC 2834 - Pharmaceutical Preparations

Split History

Stock splits are used by Eyegate Pharmaceuticals Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Peers - Pharmaceutical Preparations (2834)

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

12h - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

Related News Stories

Your Daily Pharma Scoop: Intercept's OCA, MediciNova In NASH, Pulse Biosciences Data

2018-04-16 seekingalpha
Intercept Pharmaceuticals (ICPT) reported clinical data from a liver biopsy-based substudy from its phase 3 POISE study. The study indicated that long-term OCA treatment in patients with PBC led to reversal or stabilization of fibrosis and cirrhosis. (143-3)

Office Depot, Dominion Energy Fall into Friday’s 52-Week Low Club

2018-04-13 247wallst
April 13, 2018: Here are four stocks trading with heavy volume among 52 equities making new 52-week lows in Friday’s session. On the NYSE decliners led advancers by about 3 to 2 and on the Nasdaq, decliners led advancers by about 9 to 5. (19-0)

Your Daily Pharma Scoop: Acadia Sell-Off, Therapix Soars On Results, Menlo Setback

2018-04-10 seekingalpha
Today we will discuss Acadia Pharmaceuticals (NASDAQ:ACAD), which has fallen sharply on a CNN report that raised concerns about the Nuplazid’s safety. (210-3)

Your Daily Pharma Scoop: Major Setback For Incyte, Aclaris Agreement, MannKind Offering

2018-04-07 seekingalpha
Incyte (NASDAQ:INCY) shares tumbled more than 17% as investors digested the disappointing news with regard to the company’s phase 3 study evaluating the Epacadostat/Keytruda combination in patients with unresectable or metastatic melanoma. (154-0)

BRIEF-Eyegate Pharma Submits Investigational Device Exemption Amendment For Second Pilot Study Of Ocular Bandage Gel

2018-03-08 reuters
* EYEGATE PHARMA SUBMITS INVESTIGATIONAL DEVICE EXEMPTION AMENDMENT FOR SECOND PILOT STUDY OF OCULAR BANDAGE GEL (12-1)

CUSIP: 30233M107